

Liana G Apostolova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8053955/publications.pdf>

Version: 2024-02-01

217
papers

12,039
citations

66343

42
h-index

30922

102
g-index

242
all docs

242
docs citations

242
times ranked

17225
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
3	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. <i>Brain Imaging and Behavior</i> , 2014, 8, 153-182.	2.1	696
4	Donanemab in Early Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1691-1704.	27.0	633
5	Identification of common variants associated with human hippocampal and intracranial volumes. <i>Nature Genetics</i> , 2012, 44, 552-561.	21.4	594
6	Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps. <i>Archives of Neurology</i> , 2006, 63, 693.	4.5	490
7	Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 43.	6.2	402
8	Neuropsychiatric Manifestations in Mild Cognitive Impairment: A Systematic Review of the Literature. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 115-126.	1.5	333
9	Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. <i>Neurobiology of Aging</i> , 2010, 31, 1077-1088.	3.1	261
10	Hippocampal Atrophy and Ventricular Enlargement in Normal Aging, Mild Cognitive Impairment (MCI), and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 17-27.	1.3	254
11	3D comparison of hippocampal atrophy in amnesic mild cognitive impairment and Alzheimer's disease. <i>Brain</i> , 2006, 129, 2867-2873.	7.6	232
12	Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. <i>Brain</i> , 2007, 130, 1767-1776.	7.6	229
13	New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology</i> , The, 2021, 20, 222-234.	10.2	214
14	Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. <i>NeuroImage</i> , 2009, 45, S3-S15.	4.2	211
15	Comparison of AdaBoost and Support Vector Machines for Detecting Alzheimer's Disease Through Automated Hippocampal Segmentation. <i>IEEE Transactions on Medical Imaging</i> , 2010, 29, 30-43.	8.9	184
16	Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. <i>NeuroImage</i> , 2008, 43, 59-68.	4.2	181
17	Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. <i>Human Brain Mapping</i> , 2009, 30, 2766-2788.	3.6	178
18	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	9.0	166

#	ARTICLE	IF	CITATIONS
19	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162
20	Structural Correlates of Apathy in Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 91-97.	1.5	159
21	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 687-695.	3.9	145
22	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , 2010, 31, 1284-1303.	3.1	127
23	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. <i>Alzheimer's and Dementia</i> , 2015, 11, 126-138.	0.8	123
24	Three-Dimensional Gray Matter Atrophy Mapping in Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 1489.	4.5	117
25	Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. <i>Neuropsychologia</i> , 2008, 46, 1597-1612.	1.6	116
26	Alzheimer Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 419-434.	0.8	115
27	Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. <i>JAMA Neurology</i> , 2018, 75, 328.	9.0	101
28	Reliability of twoâ€dimensional and threeâ€dimensional pseudoâ€continuous arterial spin labeling perfusion MRI in elderly populations: Comparison with 15oâ€water positron emission tomography. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 931-939.	3.4	93
29	The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1145-1155.	2.6	93
30	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. <i>Human Brain Mapping</i> , 2010, 31, 786-797.	3.6	91
31	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. <i>NeuroImage</i> , 2010, 51, 488-499.	4.2	78
32	Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 510-519.	2.4	77
33	Risk Factors for Behavioral Abnormalities in Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 315-326.	1.5	67
34	3D mapping of language networks in clinical and pre-clinical Alzheimerâ€™s disease. <i>Brain and Language</i> , 2008, 104, 33-41.	1.6	66
35	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADCâ€ADNI Harmonizedâ€Hippocampal Segmentation Protocol. <i>Alzheimer's and Dementia</i> , 2015, 11, 139-150.	0.8	61
36	3D Mapping of Mini-mental State Examination Performance in Clinical and Preclinical Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 224-231.	1.3	57

#	ARTICLE	IF	CITATIONS
37	Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2113-2124.	3.1	57
38	Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. <i>Clinical Epigenetics</i> , 2020, 12, 84.	4.1	57
39	Brain mapping as a tool to study neurodegeneration. <i>Neurotherapeutics</i> , 2007, 4, 387-400.	4.4	56
40	Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. <i>Neurobiology of Aging</i> , 2012, 33, 856-866.	3.1	55
41	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. <i>Journal of Neurology</i> , 2015, 262, 1483-1492.	3.6	53
42	Resting state network modularity along the prodromal late onset Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019, 22, 101687.	2.7	51
43	White matter alterations in early-stage Alzheimer's disease: A tract-specific study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 576-587.	2.4	50
44	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013, 34, 62-72.	3.1	49
45	Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 113-122.	2.4	47
46	Communicating mild cognitive impairment diagnoses with and without amyloid imaging. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 35.	6.2	46
47	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 461-472.	2.7	45
48	Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 57-66.	2.4	44
49	Comparing Hippocampal Atrophy in Alzheimer's Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 44-50.	1.5	43
50	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	9.0	41
51	Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADC-ADNI project. <i>Alzheimer's and Dementia</i> , 2015, 11, 151.	0.8	41
52	Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. <i>Neurobiology of Aging</i> , 2016, 39, 82-89.	3.1	40
53	Similar Verbal Fluency Patterns in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 400-410.	0.5	39
54	Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia. <i>Journal of Parkinson's Disease</i> , 2013, 3, 69-76.	2.8	38

#	ARTICLE	IF	CITATIONS
55	Age Effects on Cortical Thickness in Cognitively Normal Elderly Individuals. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 221-227.	1.3	38
56	Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7 T MRI. <i>NeuroImage: Clinical</i> , 2017, 15, 56-61.	2.7	37
57	Deep White Matter Pathologic Features in Watershed Regions. <i>Archives of Neurology</i> , 2005, 62, 1154.	4.5	36
58	The effect of the top 20 Alzheimer disease risk genes on gray matter density and FDG PET brain metabolism. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 53-66.	2.4	35
59	Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. <i>BMJ Open</i> , 2019, 9, e031947.	1.9	35
60	Epigenome-wide meta-analysis of blood DNA methylation and its association with subcortical volumes: findings from the ENIGMA Epigenetics Working Group. <i>Molecular Psychiatry</i> , 2021, 26, 3884-3895.	7.9	34
61	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.8	34
62	Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. <i>Neuroscience Letters</i> , 2011, 487, 287-292.	2.1	33
63	Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 229-237.	2.6	32
64	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 30.	5.3	32
65	Use of the MoCA in Detecting Early Alzheimer's Disease in a Spanish-Speaking Population with Varied Levels of Education. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 85-95.	1.3	31
66	Patient and caregiver reactions to clinical amyloid imaging. <i>Alzheimer's and Dementia</i> , 2017, 13, 924-932.	0.8	30
67	Tau-related white-matter alterations along spatially selective pathways. <i>NeuroImage</i> , 2021, 226, 117560.	4.2	30
68	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 154-166.	1.5	29
69	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 15-22.	2.4	29
70	Cortical and Hippocampal Atrophy in Patients with Autosomal Dominant Familial Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 118-125.	1.5	27
71	Cerebrospinal fluid A β 2 levels correlate with structural brain changes in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 302-310.	3.9	27
72	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.6	27

#	ARTICLE	IF	CITATIONS
73	Dance Experience and Associations with Cortical Gray Matter Thickness in the Aging Population. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 6, 508-517.	1.3	27
74	Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 62-68.	4.4	26
75	Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa019.	3.3	26
76	Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2018, 114, 120-128.	4.4	25
77	Cognitive Correlates of Hippocampal Atrophy and Ventricular Enlargement in Adults with or without Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 281-293.	1.3	25
78	Early diagnostics and therapeutics for Alzheimer's disease – how early can we get there?. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1293-1306.	2.8	24
79	Multilocus genetic profiling to empower drug trials and predict brain atrophy. <i>NeuroImage: Clinical</i> , 2013, 2, 827-835.	2.7	23
80	Establishing Magnetic Resonance Images Orientation for the EADC-ADNI Manual Hippocampal Segmentation Protocol. <i>Journal of Neuroimaging</i> , 2014, 24, 509-514.	2.0	23
81	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, 1213-1223.	0.8	23
82	Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 174-181.	1.3	22
83	Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness. <i>Alzheimer's and Dementia</i> , 2022, 18, 934-941.	0.8	22
84	Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 187-193.	2.4	21
85	Surface Feature-Guided Mapping of Cerebral Metabolic Changes in Cognitively Normal and Mildly Impaired Elderly. <i>Molecular Imaging and Biology</i> , 2010, 12, 218-224.	2.6	20
86	Genome-wide association study of language performance in Alzheimer's disease. <i>Brain and Language</i> , 2017, 172, 22-29.	1.6	20
87	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. <i>Brain</i> , 2022, 145, 2149-2160.	7.6	20
88	Tau Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	5.3	19
89	Optimizing differential identifiability improves connectome predictive modeling of cognitive deficits from functional connectivity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2021, 42, 3500-3516.	3.6	18
90	Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. <i>Alzheimer's and Dementia</i> , 2015, 11, 161-174.	0.8	17

#	ARTICLE	IF	CITATIONS
91	Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. <i>Neurobiology of Aging</i> , 2016, 47, 201-209.	3.1	17
92	Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 93.	6.2	17
93	The "Alzheimer's Type" Profile of Semantic Clustering in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 402-412.	1.8	16
94	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 113.	6.2	16
95	Association of Hypercholesterolemia with Alzheimer's Disease Pathology and Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1305-1311.	2.6	15
96	Social Networks and Cognitive Function: An Evaluation of Social Bridging and Bonding Mechanisms. <i>Gerontologist</i> , The, 2022, 62, 865-875.	3.9	14
97	Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans. <i>Brain Imaging and Behavior</i> , 2018, 12, 1583-1595.	2.1	13
98	Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. <i>Neurology: Genetics</i> , 2015, 1, e22.	1.9	12
99	Novel Markers of Angiogenesis in the Setting of Cognitive Impairment and Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 959-969.	2.6	12
100	Daily Activity Abilities in MCI, Alzheimer's Disease, and Healthy Controls. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2015, 28, 191-200.	0.5	12
101	Cortical Thickness and Semantic Fluency in Alzheimer's Disease and Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease (Columbia, Mo)</i> , 2013, 1, 81-92.	0.3	12
102	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. <i>NeuroImage: Clinical</i> , 2019, 21, 101574.	2.7	11
103	A comparison of theoretical and statistically derived indices for predicting cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 171-181.	2.4	10
104	Detection of tau in Gerstmann-Str�ussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET. <i>Acta Neuropathologica Communications</i> , 2018, 6, 114.	5.2	10
105	Social Networks and Cognitive Reserve: Network Structure Moderates the Association Between Amygdalar Volume and Cognitive Outcomes. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2022, 77, 1490-1500.	3.9	10
106	Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 48, 131-142.	1.5	9
107	Cognitively stimulating environments and cognitive reserve: the case of personal social networks. <i>Neurobiology of Aging</i> , 2022, 112, 197-203.	3.1	9
108	Validation of and Demographically Adjusted Normative Data for the Learning Ratio Derived from the RAVLT in Robustly Intact Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 981-993.	0.5	8

#	ARTICLE	IF	CITATIONS
109	Temporal stability of the ventral attention network and general cognition along the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2021, 31, 102726.	2.7	7
110	Predicting the Emergence of Major Neurocognitive Disorder Within Three Months After a Stroke. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 705889.	3.4	7
111	Association of the top 20 Alzheimer's disease risk genes with [¹⁸ F]flortaucipir PET. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12308.	2.4	7
112	PSYCHIATRIC MANIFESTATIONS IN DEMENTIA. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2007, 13, 165-179.	0.8	5
113	A quantitative trait approach to GWAS pays dividends. <i>Nature Reviews Neurology</i> , 2017, 13, 321-322.	10.1	5
114	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 35-42.	1.3	5
115	Atypical Alzheimer Disease Variants. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 676-701.	0.8	5
116	'Generation Next' in Alzheimer disease genetic studies. <i>Nature Reviews Neurology</i> , 2013, 9, 422-423.	10.1	4
117	Virtual reality cognitive intervention for heart failure: CORE study protocol. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12230.	3.7	4
118	ICAP-032: IMPROVING PREDICTION OF COGNITIVE OUTCOMES FROM FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P38.	0.8	2
119	Amyloid and tau PET in sporadic early-onset Alzheimer's disease: Preliminary results from LEADS. <i>Alzheimer's and Dementia</i> , 2020, 16, e041613.	0.8	2
120	Transcriptomic profiles underlying functional brain networks at different stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046163.	0.8	2
121	The Functional Ability of MCI and Alzheimer's Patients Predicts Caregiver Burden. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2019, 32, 31-39.	0.5	2
122	Associations between Cortical Thickness and Metamemory in Alzheimer's Disease. <i>Brain Imaging and Behavior</i> , 2022, , 1.	2.1	2
123	Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes. <i>Alzheimer's and Dementia</i> , 2022, , .	0.8	2
124	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.8	2
125	Assessing and validating reliable change across ADNI protocols. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 85-102.	1.3	2
126	Building a surface atlas of hippocampal subfields from high resolution T2-weighted MRI scans using landmark-free surface registration. , 2016, 2016, .		1

#	ARTICLE	IF	CITATIONS
127	ICâ€Pâ€092: Elevated Cerebral Blood Flow in Participants with Subjective Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P70.	0.8	1
128	O5â€01â€04: EXAMINING THE EFFECT OF THE TOP 20 ALZHEIMER'S DISEASE RISK VARIANTS ON BRAIN AMYLOIDOSIS, STRUCTURAL ATROPHY AND METABOLISM. Alzheimer's and Dementia, 2016, 12, P376.	0.8	1
129	ICâ€Pâ€066: Association of FDGâ€PET Brain Metabolism with Alzheimerâ€™s Disease Risk Genes. Alzheimer's and Dementia, 2016, 12, P52.	0.8	1
130	[P1â€449]: RESTING STATE NETWORK MODULARITY ALONG THE PRODROMAL LATE ONSET ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2017, 13, P457.	0.8	1
131	Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786.	2.4	1
132	Study design and clinical characteristics of the LEADS cohort. Alzheimer's and Dementia, 2020, 16, e041612.	0.8	1
133	Association of antihypertensive medications and Alzheimerâ€™s disease neuropathology. Alzheimer's and Dementia, 2020, 16, e042283.	0.8	1
134	Testing influences of APOE and BDNF genes and heart failure on cognitive function. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 51-58.	1.6	1
135	Early-Stage Alzheimer Primer. Journal of Clinical Psychiatry, 2021, 82, .	2.2	1
136	Treatment Challenges and the Hope of Emerging Therapies in Early-Stage Alzheimer Disease. Journal of Clinical Psychiatry, 2021, 82, .	2.2	1
137	Do subjective or objective cognitive measures better predict social network type among older adults?. Biodemography and Social Biology, 2022, , 1-14.	1.0	1
138	IC-P-094: Association Between N-Back Working Memory Activation on FMRI and Cognitive Assessment of Executive Function. , 2016, 12, P72-P72.		0
139	Introduction to special edition, â€œState of the Field: Advances in Neuroimaging from the 2016 Alzheimer's Imaging Consortiumâ€; Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 67-69.	2.4	0
140	P3â€147: APOE4â€Dependent Synapticâ€Derived Plasma Biomarkers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P875.	0.8	0
141	P4â€173: Elevated Cerebral Blood Flow in Participants with Subjective Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1084.	0.8	0
142	P1â€007: Association of FDGâ€PET Brain Metabolism with Alzheimerâ€™s Disease Risk Genes. Alzheimer's and Dementia, 2016, 12, P399.	0.8	0
143	ICâ€02â€01: The Effects of The Top 20 Alzheimerâ€™s Disease Risk Genes on Brain Atrophy. Alzheimer's and Dementia, 2016, 12, P4.	0.8	0
144	IC-P-057: Neuronally-Derived Exosomal Proteins Can Predict Brain Amyloidosis. , 2016, 12, P46-P47.		0

#	ARTICLE	IF	CITATIONS
145	ICâ€Pâ€059: Examining The Effect of The Top 20 Ad Risk Variants on Brain Amyloidosis, Structural Atrophy and Metabolism. Alzheimer's and Dementia, 2016, 12, P47.	0.8	0
146	IC-P-061: Alzheimerâ€™s Disease Risk Genes Can Predict Brain Amyloidosis. , 2016, 12, P49-P50.		0
147	ICâ€Pâ€070: Predicting Cognitive Decline and Brain Amyloidosis Using Cognitive and Peripheral Blood Gene Expression Measures. Alzheimer's and Dementia, 2016, 12, P55.	0.8	0
148	ICâ€Pâ€072: Gene Expression Of ABCA7 Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. Alzheimer's and Dementia, 2016, 12, P56.	0.8	0
149	ICâ€Pâ€074: Genomeâ€Wide Metaâ€Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P58.	0.8	0
150	P2â€233: Alzheimer's Disease Risk Genes Can Predict Brain Amyloidosis. Alzheimer's and Dementia, 2016, 12, P712.	0.8	0
151	P2â€249: Predicting Cognitive Decline and Brain Amyloidosis using Cognitive and Peripheral Blood Gene Expression Measures. Alzheimer's and Dementia, 2016, 12, P720.	0.8	0
152	P2â€253: The Effects of the Top 20 Alzheimer's Disease Risk Genes on Brain Atrophy. Alzheimer's and Dementia, 2016, 12, P722.	0.8	0
153	P2â€264: Association between Nâ€Back Working Memory Activation on fMRI and Cognitive Assessment of Executive Function. Alzheimer's and Dementia, 2016, 12, P728.	0.8	0
154	P3â€087: Gene Expression of <i>ABCA7</i> Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. Alzheimer's and Dementia, 2016, 12, P851.	0.8	0
155	P3-187: Neuronally-Derived Exosomal Proteins Can Predict Brain Amyloidosis. , 2016, 12, P893-P893.		0
156	ICâ€Pâ€175: Hybrid Diffusion Imaging (HYDI) of White Matter Changes in Older Adults With Subjective Cognitive Decline (SCD): Assessment of Orientation Dispersion and Axonal Density. Alzheimer's and Dementia, 2016, 12, P127.	0.8	0
157	O1â€13â€04: Effects of Cortical Amyloid β Deposition on the Incidence and Prevalence of Neuropsychiatric Behaviors in the Elderly. Alzheimer's and Dementia, 2016, 12, P210.	0.8	0
158	O2-06-02: Genome-Wide Meta-Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease. , 2016, 12, P238-P239.		0
159	P4â€328: Communicating Mild Cognitive Impairment Diagnosis with and Without Amyloid Imaging: Recommendations From An Expert Workgroup. Alzheimer's and Dementia, 2016, 12, P1160.	0.8	0
160	P4-344: Volumetric Comparison of Automatically Segmented Hippocampal Subfields From 4-Min Accelerated Versus 8-Min T2-Weighted 3T Mri Scans. , 2016, 12, P1167-P1167.		0
161	P1â€052: Damaging Effect of the Butyrylcholinesterase Kâ€Variant in Donepezil Therapy of Mild Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P421.	0.8	0
162	[P2â€356]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY VERSUS LATEâ€ONSET AMYLOIDâ€POSITIVE MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P759.	0.8	0

#	ARTICLE	IF	CITATIONS
163	[P2â€“417]: LANGUAGE FLUENCY PREDICTS RESTING STATE NETWORK CONNECTIVITY PATTERN. Alzheimer's and Dementia, 2017, 13, P793.	0.8	0
164	[P4â€“224]: AXONAL DENSITY IS ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE (SCD) IN OLDER ADULTS ASSESSED USING THE COGNITIVE CHANGE INDEX. Alzheimer's and Dementia, 2017, 13, P1355.	0.8	0
165	[P4â€“327]: PATIENT AND CAREGIVER ASSESSMENT OF THE BENEFITS FROM THE CLINICAL USE OF AMYLOIDâ€PET IMAGING. Alzheimer's and Dementia, 2017, 13, P1415.	0.8	0
166	[P4â€“386]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLYâ€VERSUS LATEâ€ONSET AMYLOIDâ€NEGATIVE MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P1440.	0.8	0
167	[ICâ€Pâ€027]: LANGUAGE FLUENCY PREDICTS RESTING STATE NETWORK CONNECTIVITY PATTERN. Alzheimer's and Dementia, 2017, 13, P25.	0.8	0
168	[ICâ€Pâ€099]: NEURODEGENERATIVE PATTERNS OF COGNITIVE CLUSTERS OF EARLY ONSET AD SUBJECTS: EVIDENCE FOR DISEASE HETEROGENEITY. Alzheimer's and Dementia, 2017, 13, P75.	0.8	0
169	[ICâ€Pâ€105]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLYâ€VERSUS LATEâ€ONSET AMYLOIDâ€POSITIVE MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P80.	0.8	0
170	[ICâ€Pâ€216]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY VERSUS LATEâ€ONSET AMYLOIDâ€NEGATIVE MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P155.	0.8	0
171	[F1â€“02â€“04]: INTEGRATING MULTIâ€MODALITY IMAGING AND MULTIâ€LAYER â€OMICS TO ADVANCE THE SYSTEMS BIOLOGY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P175.	0.8	0
172	[O3â€“03â€“02]: NEURODEGENERATIVE PATTERNS OF COGNITIVE CLUSTERS OF EARLY ONSET AD SUBJECTS: EVIDENCE FOR DISEASE HETEROGENEITY. Alzheimer's and Dementia, 2017, 13, P901.	0.8	0
173	[P4â€“479]: NEUROPSYCHIATRIC SYMPTOMS AND NEUROPATHOLOGY CORRELATION IN FRONTOTEMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2017, 13, P1517.	0.8	0
174	2307. Journal of Clinical and Translational Science, 2017, 1, 6-6.	0.6	0
175	P3â€“361: SCENEâ€ENCODING ACTIVATION AND RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1225.	0.8	0
176	P2â€“459: THE COGNITIVE CHANGE INDEX IS ASSOCIATED WITH TAU DEPOSITION ON FLORTAUCIPIR. Alzheimer's and Dementia, 2018, 14, P896.	0.8	0
177	P2â€“602: HISTORY OF HYPERCHOLESTEROLEMIA AND NEUROPATHOLOGICAL OUTCOMES. Alzheimer's and Dementia, 2018, 14, P968.	0.8	0
178	ICâ€Pâ€105: LONGITUDINAL PATTERNS OF DECLINE IN SUBTYPES OF AMNESTIC EARLY ONSET AD. Alzheimer's and Dementia, 2018, 14, P90.	0.8	0
179	P2â€“546: A COMMUNITYâ€BASED OUTREACH MODEL TO INCREASE AFRICAN AMERICAN PARTICIPATION IN AD RESEARCH. Alzheimer's and Dementia, 2018, 14, P946.	0.8	0
180	P2â€“509: HEART FAILURE PREDICTS COGNITIVE DYSFUNCTION AFTER ADJUSTING FOR <i>APOE</i> FACTORS. Alzheimer's and Dementia, 2018, 14, P927.	0.8	0

#	ARTICLE	IF	CITATIONS
181	P4â€099: MULTIVARIATE CLUSTER PROFILING OF AMYLOID BETA, TAU, NEURODEGENERATION AND VASCULAR (ATNV) BIOMARKERS IN THE ADNI COHORT: IMPLICATIONS FOR COGNITION, â€“OMICS AND CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P1475.	0.8	0
182	P3â€120: DNA METHYLATION DYNAMICS IN ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOMARKERS AND NOVEL DRUG TARGETS USING ADNI EPIGENETIC DATA. Alzheimer's and Dementia, 2018, 14, P1113.	0.8	0
183	ICâ€Pâ€108: COMBINATORIAL SENSORY MODALITY ASSESSMENT IN PRODROMAL ALZHEIMER'S DISEASE: RELATION TO MRI AND AMYLOID AND TAU PET. Alzheimer's and Dementia, 2018, 14, P92.	0.8	0
184	ICâ€Pâ€109: THE COGNITIVE CHANGE INDEX IS ASSOCIATED WITH TAU DEPOSITION ON [¹⁸ F]FLORTAUCIPIR. Alzheimer's and Dementia, 2018, 14, P93.	0.8	0
185	P3â€396: WHITEâ€MATTER MICROSTRUCTURE IN EARLY STAGE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1250.	0.8	0
186	P1â€296: COMBINATORIAL SENSORY MODALITY ASSESSMENT IN PRODROMAL ALZHEIMER'S DISEASE: RELATION TO MRI AND AMYLOID AND TAU PET. Alzheimer's and Dementia, 2018, 14, P401.	0.8	0
187	P3â€618: HIGH RED MEAT INTAKE IS ASSOCIATED WITH INCREASED TAU ON [¹⁸ F]FLORTAUCIPIR PET AND POORER MEMORY. Alzheimer's and Dementia, 2018, 14, P1367.	0.8	0
188	P2â€435: SEPARATION OF FUNCTIONAL CONNECTOMES ACROSS THE AD SPECTRUM BASED ON DISEASE SENSITIVE PRINCIPAL COMPONENTS. Alzheimer's and Dementia, 2018, 14, P879.	0.8	0
189	P2â€003: ACETYLCHOLINESTERASE INHIBITOR THERAPY IN MILD COGNITIVE IMPAIRMENT: YES OR NO?. Alzheimer's and Dementia, 2018, 14, P665.	0.8	0
190	ICâ€Pâ€219: [18F]â€AVâ€1451 BINDING PROFILE IN EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND SUSPECTED NONâ€ALZHEIMER PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P178.	0.8	0
191	ICâ€Pâ€214: HIGH RED MEAT INTAKE IS ASSOCIATED WITH INCREASED TAU ON [¹⁸ F]FLORTAUCIPIR PET AND POORER MEMORY. Alzheimer's and Dementia, 2018, 14, P175.	0.8	0
192	ICâ€Pâ€047: ASSOCIATIONS BETWEEN CORTICAL THICKNESS AND METAMEMORY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P46.	0.8	0
193	ICâ€Pâ€172: WHITEâ€MATTER MICROSTRUCTURE IN EARLY STAGE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P144.	0.8	0
194	ICâ€Pâ€044: SEPARATION OF FUNCTIONAL CONNECTOMES ACROSS THE AD SPECTRUM BASED ON DISEASEâ€SENSITIVE PRINCIPAL COMPONENTS. Alzheimer's and Dementia, 2018, 14, P43.	0.8	0
195	ICâ€Pâ€157: ALTERATIONS IN WHITEâ€MATTER DIFFUSION METRICS IN PRECLINICAL ALZHEIMER'S DISEASE: A SUBJECTâ€SPECIFIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P132.	0.8	0
196	O3â€13â€04: [18F]â€AVâ€1451 BINDING PROFILE IN EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND SUSPECTED NONâ€ALZHEIMER PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P1057.	0.8	0
197	P1â€320: ASSOCIATIONS BETWEEN CORTICAL THICKNESS AND METAMEMORY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P414.	0.8	0
198	P1â€459: LONGITUDINAL PATTERNS OF DECLINE IN SUBTYPES OF AMNESTIC EARLY ONSET AD. Alzheimer's and Dementia, 2018, 14, P494.	0.8	0

#	ARTICLE	IF	CITATIONS
199	P3â€³71: ALTERATIONS IN WHITEâ€¢MATTER DIFFUSION METRICS IN PRECLINICAL ALZHEIMER'S DISEASE: A SUBJECTâ€¢SPECIFIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P1232.	0.8	0
200	P4â€¢581: INCREASED DYNAMIC FLEXIBILITY OF FMRIâ€¢DERIVED BRAIN FUNCTIONAL CONNECTIVITY IN PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1543.	0.8	0
201	ICâ€¢Pâ€¢129: EVALUATING THE UTILITY OF HOMOLOGICAL STRUCTURAL MRI FEATURES AND A KERNELâ€¢BASED LEARNING FRAMEWORK FOR PREDICTION OF MCI. Alzheimer's and Dementia, 2019, 15, P106.	0.8	0
202	ICâ€¢Pâ€¢181: EARLY AND LATEâ€¢ONSET ALZHEIMER'S DISEASE AND SUSPECTED NONâ€¢ALZHEIMER PATHOPHYSIOLOGY WITHIN THE A/T/N FRAMEWORK. Alzheimer's and Dementia, 2019, 15, P141.	0.8	0
203	ICâ€¢Pâ€¢033: COVARYING PATTERNS OF FUNCTIONAL CONNECTIVITY WITH AMYLOID AND TAU DEPOSITION IN EARLY STAGE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P39.	0.8	0
204	ICâ€¢Pâ€¢060: GLOBAL CORTICAL [F18]FLORTALUCIPIR ASSOCIATION WITH THE TOP 20 ALZHEIMER'S DISEASE RISK GENES. Alzheimer's and Dementia, 2019, 15, P59.	0.8	0
205	ICâ€¢Pâ€¢051: PREDICTING BRAIN AMYLOIDOSIS USING PERIPHERAL BLOODâ€¢BASED GENE EXPRESSION AND EARLY STAGE NEURODEGENERATION BIOMARKERS. Alzheimer's and Dementia, 2019, 15, P52.	0.8	0
206	Audioâ€¢visual speech perception is associated with cerebral tau deposition on [18 F]flortaucipir PET. Alzheimer's and Dementia, 2020, 16, e045297.	0.8	0
207	Increased white matter MRI T1 hypointensity volume in youngâ€¢onset Alzheimerâ€¢TM's disease patients is not accounted for by age or cardiovascular risk factors. Alzheimer's and Dementia, 2020, 16, e045577.	0.8	0
208	Cognitive decline and conversion to MCI and dementia in heart failure: A 12â€¢year followâ€¢up study. Alzheimer's and Dementia, 2020, 16, e045685.	0.8	0
209	Transcriptomic profiling of brain amyloidosis using peripheral bloodâ€¢based gene expression. Alzheimer's and Dementia, 2020, 16, e046250.	0.8	0
210	Talking with Patients and Care Partners About Treatment Goals and Challenges in Early-Stage AD. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0
211	Neuroimaging improves the prediction of post-stroke major neurocognitive disorder. Journal of the Neurological Sciences, 2021, 429, 118294.	0.6	0
212	Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments. Journal of Alzheimer's Disease, 2022, 87, 761-769.	2.6	0
213	Transcriptomic profiling in mild cognitive impairment using peripheral blood gene coâ€¢expression networks. Alzheimer's and Dementia, 2021, 17, .	0.8	0
214	Cognitive, neuropsychiatric and imaging comparisons between earlyâ€¢onset and lateâ€¢onset Alzheimerâ€¢TM's disease participants from LEADS and ADNI3. Alzheimer's and Dementia, 2021, 17, .	0.8	0
215	Effect of genetic and vascular AD risk factors on rate of cognitive decline in EOAD vs LOAD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
216	Hypertension and race affect cerebral blood flow and cognition in older adults without dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
217	APOE4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056661.	0.8	0